PMID- 27566288 OWN - NLM STAT- MEDLINE DCOM- 20170601 LR - 20181113 IS - 1873-5177 (Electronic) IS - 0091-3057 (Print) IS - 0091-3057 (Linking) VI - 152 DP - 2017 Jan TI - Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. PG - 52-60 LID - S0091-3057(16)30140-X [pii] LID - 10.1016/j.pbb.2016.08.004 [doi] AB - 3,4-Methylenedioxymethamphetamine (MDMA) is a substrate for dopamine (DA), norepinephrine and serotonin (5HT) transporters that produces greater pharmacological effects on certain endpoints in females than males in both clinical and rodent preclinical studies. To evaluate potential for sex differences in abuse-related MDMA effects, the present study compared MDMA effects on intracranial self-stimulation (ICSS) and on in vivo microdialysis measurements of DA or 5HT in the nucleus accumbens (NAc) in female and male Sprague-Dawley rats. For ICSS studies, electrodes were implanted in the medial forebrain bundle and rats trained to press for electrical stimulation over a range of frequencies (56-158Hz, 0.05 log increments) under a fixed-ratio 1 schedule, and the potency (0.32-3.2mg/kg, 10min pretreatment) and time course (3.2. mg/kg, 10-180min pretreatment) of MDMA effects were determined. For in vivo microdialysis, rats were implanted with bilateral guide cannulae targeting the NAc, and the time course of MDMA effects (1.0-3.2mg/kg, 0-180min) on DA and 5HT was determined. MDMA produced qualitatively similar effects in both sexes on ICSS (both increases in low ICSS rates maintained by low brain-stimulation frequencies and decreases in high ICSS rates maintained by high brain-stimulation frequencies) and microdialysis (increases in both DA and 5HT). The duration and peak levels of both abuse-related ICSS facilitation and increases in NAc DA were longer in females. MDMA was also more potent to increase 5HT in females. These results provide evidence for heightened sensitivity of females to abuse-related behavioral and neurochemical effects of MDMA in rats. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Lazenka, M F AU - Lazenka MF AD - Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: lazenkamf@mymail.vcu.edu. FAU - Suyama, J A AU - Suyama JA AD - Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA. FAU - Bauer, C T AU - Bauer CT AD - Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA. FAU - Banks, M L AU - Banks ML AD - Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA; Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23298, USA. FAU - Negus, S S AU - Negus SS AD - Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA; Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23298, USA. LA - eng GR - P30 DA033934/DA/NIDA NIH HHS/United States GR - R01 DA026946/DA/NIDA NIH HHS/United States GR - R01 DA033930/DA/NIDA NIH HHS/United States GR - T32 DA007027/DA/NIDA NIH HHS/United States PT - Journal Article DEP - 20160824 PL - United States TA - Pharmacol Biochem Behav JT - Pharmacology, biochemistry, and behavior JID - 0367050 RN - 333DO1RDJY (Serotonin) RN - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine) RN - VTD58H1Z2X (Dopamine) SB - IM MH - Animals MH - Dopamine/metabolism MH - Dose-Response Relationship, Drug MH - Female MH - Male MH - Medial Forebrain Bundle/physiology MH - Microdialysis MH - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology MH - Nucleus Accumbens/metabolism MH - Rats MH - Self Stimulation/drug effects MH - Serotonin/metabolism MH - *Sex Characteristics MH - Time Factors PMC - PMC5195862 MID - NIHMS813382 OTO - NOTNLM OT - ICSS OT - MDMA OT - Microdialysis OT - Sex difference EDAT- 2016/08/28 06:00 MHDA- 2017/06/02 06:00 PMCR- 2018/01/01 CRDT- 2016/08/28 06:00 PHST- 2016/06/09 00:00 [received] PHST- 2016/08/13 00:00 [revised] PHST- 2016/08/22 00:00 [accepted] PHST- 2016/08/28 06:00 [pubmed] PHST- 2017/06/02 06:00 [medline] PHST- 2016/08/28 06:00 [entrez] PHST- 2018/01/01 00:00 [pmc-release] AID - S0091-3057(16)30140-X [pii] AID - 10.1016/j.pbb.2016.08.004 [doi] PST - ppublish SO - Pharmacol Biochem Behav. 2017 Jan;152:52-60. doi: 10.1016/j.pbb.2016.08.004. Epub 2016 Aug 24.